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Aromatase inhibitors (AI) are one of the main therapies to treat 
estrogen-receptor positive breast cancer. AI use is associated 
with several side effects that affects patient’s quality of life and 
reduces treatment adherence. Hence, it is necessary to make 
further efforts in elucidating and diminishing the AI-related side 
effects.  
In this line, this thesis provided new and additional evidence for 
this purpose. Starting by the importance of assessing vitamin D 
levels during AI treatment, especially to those who underwent to 
chemotherapy. We also studied the bone health evolution at the 
end and one-year after AI cessation, and the impact of oral 
bisphosphonates (BP). Moreover, we analyzed the arthralgia 
(VAS score) and health-related quality of life in osteoporosis 
(ECOS-16 score) progression during the AI treatment until one-
year post-treatment. Then, fracture incidence and risk during AI 
therapy compared to tamoxifen (TAM) was analyzed, as well as 
the protective effect of BP. Finally, we studied the cardiovascular 
and thromboembolic risk, and overall survival benefit of AI 
compared to TAM. 
Our research leads us to state that bone health and circulant 
vitamin D levels monitoring, plus calcium and vitamin D 
supplementation is key for the clinical management of AI 
patients. BP treatment is proved to diminish bone loss and 
fracture risk, but cannot reverse risk levels towards patients at 
low fracture risk. Furthermore, prior TAM treatment enhances the 
odds to withdraw during the first year, increases bone loss during 
 
 
AI treatment, and restricts the recovery in lumbar spine location 
at one-year post-treatment. On the other hand, since there are 
no differences in cardiovascular and thromboembolic risk 
between AI and TAM users, but AI users have lower all-cause 
mortality, AI should be the preferable choice. 
In summary, it is mandatory to clinical monitoring AI patients, 
especially those who were previously treated with TAM, including 
fracture risk and related risk factors assessments. These would 
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 BREAST ANATOMY  
The female breast is a subcutaneous organ located on the upper 
ventral region of the torso. The anatomy of breast is complex  
(Fig 1). It includes the mammary glands, 15-20 lobules 
separated by bands of connective tissue that produce and supply 
milk, and the ducts that transfer milk from the lobules to the 
nipple. The nipple is surrounded by a pink/brown pigmented 
region called areola. All this structure is supported and protected 
by a fatty tissue that gives the breast its soft consistency. The 
breast also contains blood vessels, lymph vessels, and lymph 
nodes. 
 
Figure 1. Anatomy of the Female Breast. External and internal 
anatomy of the female breast. Extracted from: Terese Winslow 




National Cancer Institute © (copyright year) Terese Winslow 
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 BREAST CANCER 
Breast cancer (BC) is defined as an uncontrolled grow of breast 
cells, forming a tumor, that could invade surrounding tissues 
(invasive breast cancer) or spread to distant areas of the body 
(metastatic breast cancer). Most of them begin in the ducts 
(ductal cancers), and some start in lobules (lobular cancers), 
while other types are less common. Signs of BC include a lump, 
bloody nipple discharge, or skin changes 1. BC mainly affects 
women, men can be affected but its incidence is considered rare 
(<1%) 2. This study is focus on women affected by BC. 
 
2.1 Epidemiology  
BC is the most common cancer among women (Fig 2) with an 
estimate of more than 2 million of cases detected annually 
across the world. It represented the 24.2% of diagnosed cancers 
in women at 2018. The estimated number of deaths in 2018 was 
626,679 cases, representing the 15% of female deaths caused 
by a cancer 3.  
Early detection and new treatment strategies have improved the 
survival of patients. Nowadays it is considered that 70-80% of 
them can be cured 4. 
 




Figure 2. Worldwide image of (A) incidence and (B) mortality 
of the most common type of cancer in each country. Data 
provided by GLOBOCAN 2018 database from the International 
Agency for Research on Cancer’s Global Cancer Observatory. 







2.2 General risk factors  
Epidemiologic studies have identified a list of well-known risk 
factors of BC. Those can be sorted in two types, non-modifiable 
and modifiable factors. A brief summary of the most investigated 
risk factors in each category is described below. 
 Non-modifiable factors 
2.2.1.1 Genetic factors 
Genes associated with BC can be classified according to its 
penetrance 5. 
High penetrance genes 
Highly penetrant, but rare genetic variants cause the majority of 
hereditary BC cases. Fifteen percent of familial BC are explained 
by mutations, rearrangements or deletions in tumor suppression 
genes BRCA1 and BRCA2. Female carriers have a lifetime risk 
of BC up to 85% 6. 
Other rare but highly penetrant variants are in genes involved in 
tumor suppression like PTEN (85% lifetime risk), TP53 (lifetime 
risk of 25% by age 74), CDH1 (39% lifetime risk), and STK11 
(lifetime risk of 32% by age 60). It is estimated that this genes, in 
conjunction with BRCA1 and BRCA2, explain until 25% of BC 
hereditary cases 5.  
Moderate-penetrance genes 
Genes involved in DNA repair that interact with BRCA1, BRCA2, 
and/or the BRCA pathways, and confer about a two-fold increase 
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in BC risk. Among them, there are CHEK2, BRIP1 (BACH1), 
ATM, and PALB2 genes 5. The most common mutation is 
CHEK2*1100delC, observed up to 1%–2% in general population 
7. 
These genes are designed as moderate-penetrance because 
their the genetic impact might be attenuate by environmental 
factors 5. 
Low penetrance genes 
Genetic variants common in the population and often located in 
noncoding regions of the genome, which can contribute to BC 
risk in a polygenic way, conferring very small risk increases. This 
increment of risk might be through activation of growth-promoting 
genes rather than inactivation of DNA repair, which is more 
frequent in the groups previously described. Among 
polymorphisms associated with increased risk of BC, there are 
the Pro919Ser variant in BRIP1, and noncoding regions in 2q35 
and 8q24 5. 
2.2.1.2 Hormonal risk factors 
Hormone exposure has been related to risk of sporadic BC. Sex 
hormones enhance cell proliferation, increasing the probability of 
DNA damage accumulation and promoting malignant cells 
growth. Among them, estrogens stand out as the greatest 
promoter of BC. Consequently, reproductive history and number 






Age of menarche 
Risk of BC is 10% reduced each 2 years increase in age of 
menarche. In contrast, earlier menarche, earlier thelarche – 
outset of breast development during puberty –, longer period 
between thelarche and menarche, earlier regular periods, and 
shorter time between menarche and the onset of regular periods 
are associated with an increased BC risk 8. 
Maternal age for first pregnancy and breastfeeding 
Nulliparous women 9 or advanced age at first live birth 10 
increment the risk of BC, while early pregnancy and high levels 
of estrogen during pregnancy diminish the risk 4. Moreover, each 
birth decreases the BC risk by 7% 11. 
Anothaisintawee et al. (2013)12 described a 14% lower risk of BC 
in parous Caucasian women who ever had breastfed compared 
with parous Caucasian women who never breastfed, and a 28% 
lower risk in breastfeeding longer that 12 months compared to 
shorter periods. On the other hand, The Collaborative Group on 
Hormonal Factors in Breast Cancer (2002) reported a 4.3% 
reduction in BC risk by each year of breastfeeding 11. The benefit 
of breastfeeding was independent of the number of births. 
Age of menopause 
Later menopause increases the risk of BC in 2.9% for every year 
older of menopause onset. Moreover, premenopausal women at 
identical age than postmenopausal women had an increased risk 
of 43% 13. 
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 Modifiable risk factors 
Different cultural factors, lifestyle and national awareness 
campaigns, can modify the epidemiological patterns of BC. 
Indeed, nearly 20% of BC can be attributed to modifiable risk 
factors 4.  
2.2.2.1 Overweight and obesity 
In postmenopausal women, each 5 kg/m2 increases the BC risk 
by 12% 14. In this line, obesity might increase the risk of BC in 
elderly nulliparous women 9. Conversely, association in 
premenopausal women remains uncertain: an increase in body 
mass index (BMI) was associated with an increment of BC risk in 
Asian-Pacific women, but inverse correlation was observed in 
women of other regions 14.  
2.2.2.2 Physical activity 
In postmenopausal women, several meta-analyses have found a 
12% reduction of BC risk in higher levels of physical activity 
compared to the lowest, including walking and occupational, 
recreational or household activity. On the other hand, evidence 
in premenopausal women is limited, suggesting a protective 
effect of vigorous physical activity 15. 
2.2.2.3 Alcohol use 
Daily consume of 10 gr of alcohol  ̶  approximately one drink  ̶  by 
an adult women increases BC risk in 7-10% in both, pre- and 





Both current or recent users of hormonal contraceptives have an 
average incremented BC risk of 20% compared to women who 
never used, from 9% with less than one year of use to 38% after 
ten years of exposure 16. Moreover, age of first oral 
contraceptives use has a significant linear dose–response 
relationship with BC risk: every year-old increases BC incidence 
by 0.7% 17.  
 
2.3 Breast cancer classification 
BC can be classified or descripted in many ways. One of them is 
based on tumor size, lymph node status and receptor status. All 
of them are important factors to assign the best treatment.  
 Tumor size  
The tumor size, or stage, is the extent of the breast cancer: 
Stage 0: non-invasive cancer, limited in the interior of the milk 
duct. E.g. Ductal carcinoma in situ (DCIS).  
Stage I-III: stage I tumors are relatively small with no or a minor 
spreading to the sentinel lymph node (the first lymph node 
affected by the cancer). Stages II and III have larger size and 
spreading to nearby lymph nodes. Specially stage III, that can 
grow into nearby tissues, and affects more adjacent lymph 
nodes. 
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Stage IV: metastatic BC that has spread outside the breast and 
nearby lymph nodes to other parts of the body. 
Recurrent breast cancer: cancer that returns after a primary 
treatment. It can appear in the same breast or in the surgery scar 
(local), in the nearby lymph nodes (regional), or in a distant area. 
 
 Lymph node invasion 
Lymph nodes and lymph vessels collects and transport fluids, 
filed with waste materials, viruses and bacteria, among others, 
independently of the bloodstream. When a BC is spreading, the 
first invaded tissue is frequently the lymph nodes under the arm 
(axillary lymph nodes). The first lymph node – or group of lymph 
nodes – affected by the primary tumor is termed the sentinel 
lymph node. Occasionally, lymph nodes near the clavicle or near 
the sternum are also invaded.  
Lymph node invasion is classified by categories (N) from 0 to 3, 
according to the number of invaded nodes: 
N0: cancer has not invaded any lymph node. 
N1: cancer has extended to 1 to 3 axillary lymph nodes, and/or it 
can be found in internal mammary lymph nodes on sentinel 
lymph node biopsy. 
N2: cancer has extended to 4 to 9 axillary lymph nodes, and/or it 
has enlarged the internal mammary lymph nodes. 
N3: cancer has spread greater than 2 mm at least in one area, 




the infraclavicular nodes. Other variations are invasion of axillary 
lymph node bigger than 2 mm plus enlargement of the internal 
mammary lymph nodes, or plus supraclavicular nodes invasion.  
 Receptor status 
At the time of diagnosis, the presence of receptors in tumor cells 
is evaluated.  
2.3.3.1 Hormone receptor positive 
Estrogen receptor (ER) 18,19 and progesterone receptor (PR) 20 
regulate the cell proliferation and differentiation in target tissues, 
like breast. Tumors with positive expression (+) of ER and/or PR 
are denominated hormone receptor positive (HR+). This occurs 
approximately in 70-80% of BC diagnosis 21.  
2.3.3.2 HER2-positive  
Human epidermal growth factor receptor 2 (HER2) gene codifies 
for the protein HER2. Its function is to activate intracellular 
signaling pathways in response to extracellular signals22.  
HER2 gene amplification or HER2 protein overexpression leads 
to an overgrown of the tumor cells. This BC is determined as 
HER2+ and it is observed in 15-20% of all BC. This subtype is 
more aggressive and has an increased mortality than HR+ 23. 
2.3.3.3 Triple negative 
Tumor cells with no presence of ER, PR and HER2 are 
determined as triple negative. Generally, this form is more 
common in younger women (<40 years old), who are African-
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American or who have BRCA1 gene mutation 24. Likewise, it has 
been associated with central obesity in premenopausal women25. 
Triple negative is more aggressive, its’ grow and spread is faster 
than HR+ and HER2+, and it represents the 15-20% of all BC 
26,27. 
 
 ESTROGEN RECEPTOR POSITIVE BREAST 
CANCER 
Within HR+ BC, overexpression of ER is detected in 60-70% of 
cases 28. Its binding with estrogens promotes cell proliferation in 
breast tissue, which has been associated with an increase in BC 
risk (as it is mentioned in section 2.2.1.2). Furthermore, products 
of the estrogen metabolism have been described as carcinogens 
29. 
Therefore, estrogen pathway, ER, and their implication in BC are 
further explained below:  
 
3.1 Estrogen pathway 
Estrogens are the main sex hormones in women. These steroids 
control the development and regulation of the reproductive 
system during women’s life. Moreover, estrogens play a role in 
the regulation of different metabolic target tissues, including 
adipose tissue, skeletal muscle and liver, among others 30.  




Estradiol (E2 or 17β-estradiol): The most potent and abundant 
estrogen during woman's reproductive years. It is indispensable 
for the development and growth of the mammary glands. 
Estrone (E1): The second most potent estrogen. E1 can be 
transformed into estradiol. Its conjugate, the estrone sulfate, is 
inactive and it acts as an estrogen reservoir. After menopause, 
E1 plays a greater role in women, becoming the most common 
estrogen. 
Estriol (E3): The less potent estrogen. It is obtained after the 
16α-hydroxylation of E1 in the liver. E3 plays a larger role during 
pregnancy when it is produced in large quantities by the 
placenta. 
 
Figure 3. Chemical structure of the three types of estrogens: 
estrone, estradiol and estriol. Modified from: KEGG 
COMPOUND Database. 
From puberty to menopause, the primary source of estrogens is 
synthetized in the ovaries. After menopause, ovaries stop the 
estrogen production but maintain the synthesis of its precursors: 
androstenedione and testosterone. These androgens are 
converted into estrone in peripheral tissues through aromatase 
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enzyme, i.e. adipose tissue, adrenal glands, bone, muscle, and 
skin 27,32. (Fig 4)  
  
 
Figure 4. Main steroidogenic pathways involved in estrogen 
synthesis. Enzymes are shown in boxes and metabolites are 
emphasized in bold. Dash arrow indicates poor flux from 17-OH-
progesterone (17-hydroxyprogesterone) to androstenedione via 
P450c17. 
 
3.2 Estrogen receptor 
ER is a nuclear hormone receptor that principally triggers the 
cellular proliferation and differentiation, and the regulation of 
apoptosis 33. There are two isoforms, ERα 18 and ERβ 19.  
ERα is an activator of estrogen effects, while dimerization of 
ERα-ERβ inhibits its actions 34. Concentration of both subtypes 
depends on target tissue and age, but the main regulator of 




ER signaling pathway is displayed in Figure 5. 
 
Figure 5. Signaling pathway of Estrogen Receptor.  
Estrogens (orange box) bind to estrogen receptor (ER). The 
estrogen-ER complex binds to estrogen-response element 
(ERE), recruiting distinct coregulatory proteins (co-activators, 
CoA; and co-repressors, CoR) and then, triggering the gene 
transcription. Conversely, an independent activation of the 
genomic transcription can be triggered by growth factors, 
through the activation of protein kinase cascades (i.e. ras; 
phosphatidylinositide 3-kinase, PI3K; extracellular signal–
regulated kinase, ERK; and akt proteins). Modified from: Rong C, 
et al. Estrogen Receptor Signaling in Radiotherapy: From 
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Molecular Mechanisms to Clinical Studies. Int J Mol Sci. 
2018;19(3). 
 
3.3 Estrogen implication in breast cancer 
High levels of endogenous estrogen in postmenopausal women 
have been associated with increased BC risk 36.  
Hormone exposure is a major risk factor for sporadic breast 
cancer 4. A key factor for the BC initiation is the oxidative 
metabolism of estrogens, which induces damage in DNA and 
thus, predisposition to BC (Fig 6) 29. Moreover, proliferation of 
ER+ BC cells are promoted by estrogens via ER.  
 
Figure 6. Metabolic pathway for estrogen carcinogenesis.  




formation of the 2-OH- and 4-OH-estrogens, which are known as 
catechol estrogens (CEs). Specially CE-3,4-quinones (CE-3,4-
Q),  are capable of starting the cancer process by binding to 
DNA and forming depurinating DNA adducts, 4-OHE1(E2)-1-
N3Ade and 4-OHE1(E2)-1-N7Gua. The cleavage of these 
depurinating adducts generates apurinic sites in DNA that may 
induce mutations, and therefore, could initiate cancer. 
Additionally, catechol-O-methyltransferase (COMT) inhibition 
increments the amount of oxidative DNA damage and 
depurinating adducts. On the other hand, generation of free 
radicals and reactive oxygen species (ROS) by redox cycling of 
quinone (Q) and semiquinone (SQ) metabolites, stimulates 
mammary carcinogenicity progression through redox signal 
pathway activation, and increases genomic instability. E1, 
estrone; E2, estradiol; NQO1, NAD(P)H-Quinone oxidoreductase 
1; MtDNA, mitochondrial DNA; CYP, cytochrome P450. 
Extracted from: Wen C. et al. Unifying mechanism in the initiation 
of breast cancer by metabolism of estrogen (Review). Molecular 
Medicine Reports. 2017;16(1001-1006). 
 
 THERAPIES FOR ESTROGEN RECEPTOR 
POSITIVE BREAST CANCER 
Specialists recommend the treatment choice according to tumor 
characteristics, maximizing overall survival, disease-free survival 
and the quality of life. 
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Neoadjuvant treatments – those administered before the surgery 
– are advised for larger breast tumors (>2 cm), and inflammatory 
or locally advanced cancers. These preoperative procedures can 
reduce the size of tumor enough to allow the surgery. In case of 
early BC, neoadjuvant treatments can be suitable to treat 
invaded axillary nodes in order to downstage the cancer from N1 
to N0 37. 
On the other hand, adjuvant treatments – those administered 
post-surgery – are designed to diminish patient exposure to 
potentially toxic therapies, and to avoid micrometastasis and 
recurrences 37. 
This thesis is focused on therapies for ER+ BC and, in particular, 
on aromatase inhibitors as adjuvant therapy. 
 
4.1 Surgery  
Removal of the cancer cells in the breast is commonly a key step 
for BC treatment. The most commons are the breast-conserving 
surgery and the mastectomy 38,39. 
The breast-conserving surgery is the first surgical choice. This 
type of surgery removes the breast tumor and a small zone 
around the abnormal tissue, preserving the remaining breast. 
Mastectomy removes the entire breast, leaving the chest muscle. 
Both are generally followed by radiation therapy in order to 




In the same surgery or as a separate procedure, a biopsy of 
sentinel lymph nodes or an extirpation of axillary lymph nodes 
might be incorporated 38. 
 
4.2 Radiotherapy 
Radiotherapy uses high-energy X-rays to damage DNA in cancer 
cells, killing them or avoiding their replication.  
After breast-conserving surgery, whole-breast radiotherapy is 
strongly recommended. It is directed to the entire breast, and it 
reduces the 10-year risk of any first recurrence and the 15-year 
risk of breast cancer-related mortality by 15% and 4%, 
respectively 40. For patients with a low risk for local recurrence, a 
shorter treatment time is suitable (accelerated partial-breast 
radiotherapy) 39. 
After mastectomy, it is recommended to irradiate the chest wall 
(post-mastectomy radiotherapy), and it often includes the 
regional lymph nodes that drain the breast. In node-positive 
patients, it diminish the 10-year risk of any recurrence by 10%, 




Growth and division of cancer cells are faster than normal cells. 
Chemotherapy is a treatment that uses cytotoxic agents – alone 
or in combination – that stop the cell division, diminishing the 
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fast-growing cells progression or even killing them. Thus, 
chemotherapy affects tumor cells larger than normal cells.  
It can be administrated orally or intravenously, before or after the 
surgery. Its indication in ER+ BC depends on the risk of relapse 
and recurrence, and it is advisable if lymph nodes are affected 
37,39. 
 
4.4 Endocrine therapy 
Endocrine therapy is an adjuvant treatment that stops estrogen 
production and/or action, in order to diminish the risk of 
promoting the grow of residual cancer cells. Patients with 
detectable ER expression are suitable for endocrine therapy, 
regardless the use of chemotherapy and/or targeted therapy.  
The principal therapies for ER+ BC are tamoxifen (TAM) and 
aromatase inhibitors (AI). It can also be called as hormonal 
therapy or antiestrogenic therapy. Current recommendations 
distinguish between ‘initial therapy’ (to complete 5 years of 
antiestrogenic therapy) and ‘extended adjuvant therapy’ (for 
extending from 5, up to 10 years) (Fig 7). The extension of the 
treatment over the 5 years can be advisable for patients with 





Figure 7. Endocrine treatment recommendations for 
estrogen receptor positive breast cancer according to NCCN 
guidelines. AI, aromatase inhibitors; ET, endocrine therapy; 
TAM, tamoxifen; y, years. Adapted from: NCCN Guidelines 
Version 1.2020 Breast Cancer. 
 
 Tamoxifen 
TAM is a selective estrogen-receptor modulator (SERM). In 
breast tissue, TAM acts as a competitive inhibitor: it binds to ER, 
changing the receptor conformation and blocking the signal 
pathway (Fig 8). 
TAM is the standard treatment for pre- and perimenopausal 
women with ER+ BC (Fig 7). Five years of TAM use in ER+ BC 
patients can reduce their annual BC death rate by 31% 43. For 
larger reductions, ovarian suppression by gonadotropin-releasing 
hormone (GnRH) agonists or ovarian ablation might be 
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considered during TAM treatment. Data on overall survival of 
these patients remains immature, but SOFT trial reported an 
update showing an improvement of overall disease-free survival 
in TAM plus ovarian suppression in the premenopausal cohort 
who had received chemotherapy 44,45. In case of becoming 
postmenopausal during the initial therapy of TAM, a switch to an 
AI seems to be positive 39,41. 
 
Figure 8. Schematic mechanism of action of tamoxifen and 
aromatase inhibitor to suppress estrogen signaling in an 
ER-positive cell. Tamoxifen competes against estrogens to bind 
estrogen receptor (ER), whereas aromatase inhibitor blocks the 




pathway, inhibiting cell grow and proliferation of estrogen-
induced breast cancer cells. EREs, estrogen-response elements 
(EREs). Adapted from: Johnston SR, Dowsett M. Aromatase 
inhibitors for breast cancer: lessons from the laboratory. Nature 
reviews Cancer. 2003;3(11):821-831. 
In contrast to breast tissue, TAM has an estrogen-like effect on 
bone metabolism, potentially by reducing bone resorption  
and turnover, and stimulating bone formation 46,47. In 
postmenopausal women, TAM has been associated with 
maintenance of lumbar spine and femoral neck BMD 48. Despite 
the long-term use in healthy premenopausal women was related 
to BMD reduction 49, Kim et al. described a preservation of BMD 
in premenopausal women diagnosed with BC 50. 
On the other hand, TAM use has been associated with an 
increased risk of venous thromboembolism events, endometrial 
cancer and cataracts 51. 
 
 Aromatase Inhibitors 
As it was described in section 3.1, estrogen synthesis in ovaries 
stops in the menopause, and then the main source of estrogen is 
obtained from the peripheral conversion due to the aromatase 
enzyme. AI block the aromatase enzyme, impeding the 
conversion of androstenedione and testosterone into estrogens 
(Fig 8). Hence, AI are not suitable for women with functional 
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ovaries due to their incapability to block ovarian production of 
estrogen 52. 
The currently dispensed AI belong to the third generation, which 
are greater selective for the aromatase enzyme and better 
tolerated compared to the previous generations 53. Inhibition of 
aromatase enzyme reduces over 98% of the circulating estrogen 
in postmenopausal women 54,55. Among the third generation, we 
can distinguish two types of drugs depending on the nature of 
the binding to the aromatase: non-steroidal (reversible binding), 
which are anastrozole and letrozole; and steroidal (irreversible 
binding), which is exemestane 53. Nonetheless, there are no 
significant differences in efficacy between them 56,57. 
Several studies have found that AI use in postmenopausal 
women is more effective reducing the risk of BC recurrence and 
mortality than TAM 58-60: compare to TAM, AI use can reduce the 
risk of recurrence by 30% during treatment, but not thereafter; 
and 10-year BC mortality rates by 15% after 5 years of 
monotherapy, which would correspond to 40% compared with no 
endocrine treatment 61. Therefore, guidelines recommend 
switching from TAM to AI after reaching menopause, to complete 
the 5 years of antiestrogenic therapy 37,39,42. Likewise, ovarian 
suppression plus AI should be considered for premenopausal 
women at high risk of recurrence 37,38,62.  






 SIDE EFFECTS OF AROMATASE INHIBITORS 
Estrogen deprivation by AI use has several side effects. These 
affect the quality of life, treatment adherence and the associated 
mortality of patient 60.  
5.1 Musculoskeletal events 
Musculoskeletal events are the most common side effects of AI 
use. It is estimated to affect around 50% of patients 63, and 
several studies considered them the first cause of 
discontinuation64,65.  Among musculoskeletal toxicities, arthralgia 
and bone loss induction stand out.  
 AI impact on joint pain 
Arthralgia is described as pain in the joins, affecting wrists, 
hands, and knees. Generally, it is presented symmetrically 63. 
Other common complaints or described symptoms are carpal 
tunnel syndrome, trigger finger, morning stiffness, myalgia, and 
decreased grip strength 66,67. Development of arthralgia might 
occur from the first month to two years of treatment 68, but the 
most frequently is within the first three months 69. A meta-
analysis from Beckwee et al. (2017) reported prevalence of 46% 
70.  
The etiology and physiopathological mechanisms of AI-related 
arthralgia remain unknown. Although it has never been proved, 
the most common thought is that estrogen depletion causes the 
joint pain 71. One hypothesis is that estrogens depletion might 
alter pain sensitivity, decreasing the pain threshold. Another 
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hypothesis is that estrogen drop increments the release of 
cytokines, exacerbating bone loss and aging, and leading to pain 
72. 
 AI impact on bone 
Estrogens contribute in bone health by promoting osteoblasts 
activity and inhibiting osteoclast resorption (Fig 9). Estrogen 
deficiency leads to an impairment in bone remodeling, 
unbalancing bone resorption and formation, which accelerates 
bone loss 73. Several randomized control trials (RCT) have 
reported an enhanced decrease of bone mineral density (BMD) 
74-76, leading to osteopenic or osteoporotic bone status. 
Osteoporosis – or porous bone – is a condition where bone 
becomes fragile. It is characterized by bone mass reduction and 
deteriorated bone microarchitecture, leading to fragility fractures. 
Osteoporotic fractures are associated with an increment in 
morbidity and mortality, specially hip and vertebral fractures 77,78. 
Osteopenia is the previous stage of osteoporosis, where bone 
mass is lower than “young normal” adult but not as much to be 
considered as pathologic 79. Explanation of bone status 
classification is detailed in 6.2.1 section. Briefly, the World Health 
Organization established osteopenia and osteoporosis as having 
a bone densitometry T score at spine, hip, or forearm between -1 
to -2.5, and ≥-2.5 standard deviations (SD), respectively 80.  
Women in the menopause reduce drastically the circulating 
estrogen levels and AI treatment declines the remaining 




at least 2-fold higher bone loss than healthy, age-matched 
postmenopausal women 81 and, compared to TAM patients, AI 
users have 35% more risk of fracture 82. Likewise, bone 
microarchitecture is deteriorated during AI treatment 83,84.  
 
Figure 9. Estrogens action for bone health maintenance. 
Estrogens enhance bone formation by expanding osteoblasts 
lifespan and inhibiting its apoptosis, while inhibits osteoblasts 
function and contributes to its apoptosis. Obtained from: Angela 
Hirbe et al. Skeletal Complications of Breast Cancer Therapies. 
Clin Cancer Res. 2006;(12) (20) 6309s-6314s. 
 
5.2 Cardiovascular events 
Cholesterol levels are commonly used as predictors of 
cardiovascular events. Bell et al. (2012) observed an alteration of 
the lipid profile at three months of AI treatment: levels of high-
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density lipoprotein (HDL) diminished, levels of low-density 
lipoprotein (LDL) increased, and therefore, LDL/HDL ratio was 
higher 85. BIG 1-98 and ATAC trials reported an increased 
hypercholesterolemia in AI users compared to TAM users 86,87. 
Conversely, no significant differences were observed between 
extended adjuvant letrozole therapy and placebo in MA-17 trial 
88. In the same line, results from other RCT and meta-analyses 
evaluating cardiovascular events are heterogeneous 89,90. 
Hence, there is no clear effect of AI on cardiovascular risk. 
 
 MANAGEMENT OF SECONDARY EFFECTS 
CAUSED BY AI TREATMENT 
6.1 Management of arthralgia 
Arthralgia is one of the principal factors involved in AI therapy 
discontinuation. Hence, diminishing the impact of arthralgia in 
patients would decrease treatment dropout rates.  
Pain evaluation is complex since patient's perception can include 
several physiological processes. Self-report is considered the 
gold standard way of communication in patients with verbal 
capacities, while external signs of pain like crying are secondary. 
Likewise, assessment of pain severity should be performed 
before and after potentially painful interventions. Different 





Figure 10. Examples of pain scales for quantifying pain as it 
is occurring. Extracted from: www.msdmanuals.com/ 
professional/neurologic-disorders/pain/evaluation-of-pain# 
Although there is no clear consensus about how manage AI-
related arthralgia, guidance and education before stating AI has 
been described as a key factor. Physicians can recommend 
different lifestyle modifications that might reduce joint symptoms, 
including exercise and weight reduction 92,93. Switching to 
another AI can be a different approach in cases of extreme pain 
since some patients experimented a decline in the intensity of 
side effects after switching 94,95. Other interventions that have 
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been studied included acupuncture, diuretic therapy, 
corticosteroids, antidepressants, supplementation of vitamin D, 
and supplementation of omega-3 fatty acids. Likewise, the use of 
bisphosphonates (BP) has been associated with a lower 
incidence of arthralgias 96.  
 
6.2 Management of bone loss 
A baseline evaluation of fracture risk before treatment starting 
and bone status monitoring during AI therapy is strongly 
recommended in order to preserve and/or restore bone health. 
Baseline evaluation should include a detailed medical history, 
physical examination, laboratory assessment, and BMD 
assessment, to detect fracture risk factors 97. Although there is 
no optimal schedule for establishing a periodic assessment 
during AI use, there is a treatment algorithm originally designed 
by Hadji et al. (2008) and adapted by Rachner et al. (2018) (Fig 
11) 98,99.  
 Bone mineral density assessment and 
antiresorptive treatment 
BMD is evaluated by bone densitometry (also called dual-energy 
x-ray absorptiometry, DXA or DEXA) in lumbar spine, femoral 
neck and total hip. Obtained BMD values are compared with 
young adult values using T-scores to determine bone status: a T-
score equal or higher than -1 SD is considered normal, a T-score 
lower than -1 SD but higher than -2.5 SD is classified as 




diagnosed as osteoporosis. Patient is categorized according to 
T-score value 80.  
 
Figure 11. Proposed algorithm for managing bone health in 
patients with breast cancer receiving aromatase inhibitor 
therapy. These recommendations were based on trials results 
from breast cancer patients and healthy populations. Initial 
stratification uses the lower T-score from lumbar spine, femoral 
neck and total hip. If patients’ bone mineral density decreases by 
≥ 10% annually (using the same dual-energy x-ray 
absorptiometry machine), evaluation of secondary causes of 
bone loss as vitamin D deficiency and initiation of antiresorptive 
therapy is advisable. BMD, bone mineral density; GnRH, 
gonadotropin-releasing hormone. Obtained from: Rachner TD et 
al. Bone health during endocrine therapy for cancer. Lancet 
Diabetes Endocrinol. 2018;6(11):901–910. 
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Exercise and supplements of calcium and vitamin D are 
recommended for all AI treated patients. As well as general 
population, those patients diagnosed with osteoporosis should 
be treated with antiresorptives. Use of antiresorptive drugs is 
also advisable in case of women with a T-score ≤ -2 SD at any 
site, plus prevalent fragility fractures or one major risk factor (e.g. 
family history of femoral fracture, previous osteoporotic fracture, 
early menopause, and smoking) 100. 
Antiresorptive treatments inhibit osteoclast resorption, increasing 
BMD and reducing fracture risk. For the management of AI-
related bone loss, clinical guidelines recommend BP or, in case 
of BP intolerance or low adherence, denosumab 100: BP induce 
mature osteoclast apoptosis, and decrease differentiation and 
recruitment of osteoclast precursors. Thus, cellular remodeling 
process is not completely stopped, but the number of mature 
active osteoclasts is greatly reduced 101. On the other hand, 
denosumab is a monoclonal antibody against the receptor 
activator of the NF-κB ligand (RANKL). RANKL binding to 
receptor RANK in osteoclast surface promotes bone resorption, 
and high concentrations of this molecule promote osteoclast 
development 99.  
 Other risk factors assessment 
Despite BMD predicts about 70% of bone strength 102, additional 
assessments can provide extra information that may identify 
other patients that would not be previously considered at high 




6.2.2.1 Bone microarchitecture and trabecular bone 
score 
Deterioration of bone microarchitecture increases bone fragility 
and therefore fracture risk. Trabecular bone score (TBS) is a 
textural index that evaluates bone microarchitecture through an 
assessment of the pixel gray‑level variations from a lumbar spine 
DXA image (Fig 12). This noninvasive analytical method works 
for any available DXA image, even if it was obtained years 
before 103.  
 
Figure 12. Representation of Trabecular Bone Score 
principles. The TBS software analyses the DXA scan. An 
algorithm evaluates the spatial organization of pixel intensity, 
obtaining an overall score – the trabecular bone score (TBS) –. 
As it is exemplified in the figure, TBS is independent from bone 
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mineral density (BMD): despite a very similar BMD values 
between the two represented patients, TBS values differs. As a 
principle, a high TBS value represents a dense trabecular 
microstructure, more numerous and connected and less sparse 
trabeculae; while a low value represents a porous trabecular 
structure, less numerous and connected, and high trabecular 
separation. Extracted from: Barbara C Silva et al. Trabecular 
Bone Score: A Noninvasive Analytical Method Based Upon the 
DXA Image. Journal of Bone and Mineral Research. 
2014;29(3):518-530. 
By analogy with the three BMD categories, a range for 
postmenopausal women was proposed: TBS ≥1.350 is 
considered normal, between 1.200 and 1.350 is considered 
partially degraded, and TBS ≤1.200 is defined as degraded 
microarchitecture 103. 
In AI users, TBS may potentially help to distinguish between 
patients with a threshold BMD (near to osteoporosis diagnosis) 
who are at high risk for fracture versus those who are not, and 
therefore, enhance monitoring and/or initiate antiresorptive 
treatment if necessary. 
6.2.2.2 Bone turnover markers 
The metabolic activities of osteoclasts and osteoblasts can be 
captured by bone remodeling markers. Estrogens decline during 
menopause leads to an increase of bone resorption markers 
such as C-telopeptide (CTX) and N-telopeptide (NTX), and a 




phosphatase (BAP), osteocalcin (OC) and amino-terminal 
propeptide of type I procollagen (PINP) 104. AI therapy has been 
associated with a greater increase in bone resorption markers 
than average postmenopausal values, whereas bone formation 
markers may either decrease or increase 105. 
Ideally, change of bone turnover markers after AI therapy outset 
would be useful for predicting and identifying women at high-risk 
of bone loss. Although there is no available prediction model for 
AI treated women, evaluation of bone remodeling markers can 
help physician to control the effect of AI as well as effectiveness 
of antiresorptive treatment. 
6.2.2.3 Fracture Risk Assessment Tool 
Fracture Risk Assessment Tool (FRAX®) is a predictive 
computer algorithm that predicts the 10-year risk of hip fracture, 
and the 10-year risk of major osteoporotic (i.e. clinical spine, 
forearm, hip or shoulder) fracture 106. However, FRAX might not 
be very suitable for AI patients since this tool was not designed 
for women with breast cancer, and AI therapy may be 





















The main objective is to evaluate the impact of AI side effects 
and its risks factors in order to improve the quality of life of 
patients and therefore, to avoid or reduce the treatment 
discontinuation. 
Thus, the specific objectives planned in this thesis are the 
following: 
1. Evaluation of vitamin D levels of patients starting AI treatment 
in the B-ABLE cohort.  
1.1. To determine the vitamin D status of postmenopausal 
women diagnosed with ER+ BC before starting AI treatment. 
1.2. To detect factors contributing to vitamin D levels in ER+ BC 
patients. 
 
2. Assessment of bone health in ER+ BC patients one year after 
complete AI treatment in the B-ABLE cohort. 
 
3. Assessment of life quality and treatment discontinuation of 
AI-treated patients in the B-ABLE cohort. 
3.1. To evaluate the evolution of joint pain and health-related 
quality of life during AI treatment until 1-year after AI 
completion in the B-ABLE cohort. 
3.2. To determine the proportion of early cessation of AI 
treatment caused by AI intolerance in the B-ABLE cohort. 
3.3. To estimate the effect of previous TAM exposure on AI 





4. Analysis of fracture incidence and risk during AI therapy and 
evaluation of the effectiveness of oral bisphosphonates in 
reducing fracture risk: the SIDIAP study. 
4.1. To estimate the incidence of fractures during AI treatment in 
the SIDIAP database. 
4.2. To estimate the fracture risk during AI treatment compared 
with TAM treatment in the SIDIAP database. 
4.3. To evaluate the effectiveness of oral bisphosphonates in AI-
treated patients at high risk of fracture in SIDIAP database. 
 
5. Analysis of cardiovascular risk, thromboembolic risk, and 
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Title: Vitamin D levels in Mediterranean breast cancer patients 
compared with those in healthy women 
Summary: 
To assess the vitamin D status of postmenopausal women with 
early estrogen-receptor-positive breast cancer and compare it to 
healthy postmenopausal women from the same Mediterranean 
region, data from 691 breast cancer patients (BC) in the B-ABLE 
cohort were analyzed: subsequent to recent cancer intervention 
(recent-BC) or after a minimum of two years from this 
intervention (long-term-BC). Additionally, patients were stratified 
by prior chemotherapy exposure (ChT+ and ChT-). Plasma 
concentrations of 25-hydroxyvitamin D [25(OH)D] (25(OH)D) 
were contrasted with data from 294 healthy women (non-BC) to 
estimate β-coefficients through linear regression. Age, body 
mass index and season of blood collection were used as 
confounders, and non-BC participants were used as reference 
group. A 23.7% of recent-BC patients had 25(OH)D deficiency, 
followed by 17.7% in long-term-BC group, and just 1.4% of non-
BC participants. Most women were in the insufficient 25(OH)D 
category regardless of study group. BC patients had significantly 
lower 25(OH)D levels than non-BC participants (adjusted  
β-coefficients: -4.84 [95%CI: -6.56 to -3.12] in recent-BC, and  
-2.05 [95%CI: -4.96 to -0.14] in long-term-BC). Among BC 
patients, the lowest 25(OH)D levels were found in recent-BC 
(ChT+) (p<0.001). There were no differences between long-term-




Considering only BC patients ChT+, results showed significant 
reduced 25(OH)D levels in recent-BC compared to long-term-BC 
(p<0.001). 
In conclusion, breast cancer patients exhibited severely reduced 
25(OH)D, especially after recent chemotherapy. These 25(OH)D 
levels would be partially recovered at long-term but remaining 
much lower than in the healthy population. 
Reference:  
Pineda-Moncusí M, Garcia-Perez MA, Rial A, Casamayor G, 
Cos ML, Servitja S, Tusquets I, Diez-Perez A, Cano A, Garcia-
Giralt N, Nogues X. Vitamin D levels in Mediterranean breast 
cancer patients compared with those in healthy women. 
Maturitas. 2018 Oct;116:83-88. Epub 2018 Jul 29. PubMed 

























Title: Bone health evaluation one year after aromatase inhibitors 
completion 
Summary: 
Breast cancer patients using aromatase inhibitors (AIs) 
experience an increased bone loss during their treatment. 
However, there is a scarcity of information about bone mineral 
density (BMD) after AI-treatment completion. Hence, we aimed 
to assess BMD changes one year after completing AI-therapy. 
Data from 864 postmenopausal women treated with AI for 
5 years (5y-AI group), or for 2-3 years after taking tamoxifen 
therapy (pTAM-AI group), were collected. Those with 
osteoporosis were treated with oral bisphosphonates (BP). 
Changes in lumbar spine (LS), femoral neck (FN) and total hip 
(TH) BMD between baseline, end of treatment, and one-year 
post-treatment were evaluated using repeated-measures 
ANOVA. At the end of AI-treatment, 382 patients had available 
BMD values and 316 also had post-treatment BMD values.  
As expected, BMD levels were decreased at AI-completion in 
non-BP treated patients. After one year, LS BMD improved in 
both groups (5y-AI: +2.11% [95%CI: 1.55 to 2.68], p < 0.001; 
pTAM-AI: +1.00% [95%CI: 0.49 to 1.51], p < 0.001) compared 
with the end of AI-therapy, while FN and TH values remained 
stable. On the other hand, BMD values of women treated with 
BP were increased or maintained at the end of AI-treatment and 




In summary, FN and TH BMD continued diminished in non-BP 
treated patients one year after AI-completion, while LS BMD was 
restored in the 5y-AI group and partly restored in the pTAM-AI 
group. BP treatment increased or maintained BMD values at the 
end of therapy and at one-year post-treatment. 
Reference: 
Pineda-Moncusí M, Servitja S, Casamayor G, Cos ML, Rial A, 
Rodriguez-Morera J, Tusquets I, Diez-Perez A, Garcia-Giralt N, 
Nogués X. Bone health evaluation one year after  
aromatase inhibitors completion. Bone. 2018 Dec;117:54-59.  








































AI intolerance (n (%)) 33 (27.0%) 0 (0%) 
BP intolerance (n (%)) 3 (2.5%) 0 (0%) 
Concomitant disease (n 
(%)) 
 13 (10.7%) 0 (0%) 
Exitus (n (%)) 3 (2.5%) 0 (0%) 
Extended AI-treatment (n 
(%)) 
N/A 6 (14.6%) 
Metastasis (n (%)) 10 (8.2%) 0 (0%) 
Personal reasons (n (%)) 36 (29.5%) 33 (80.5%) 
Recurrence (n (%)) 13 (10.7%) 1 (2.4%) 
Second neoplasms (n (%)) 11 (9.0%) 0 (0%) 
Use of corticoids (n (%)) 0 (0%) 1 (2.4%) 
Abbreviations: AI, aromatase inhibitors; BP, oral 
bisphosphonates; N/A, not applicable. 
 







Clinical vertebral (n (%)) 4 (30.8%) 8 (27.6%) 
Femur (n (%)) 1 (7.7%) 3 (10.3%) 
Colles (n (%)) 2 (15.4%) 8 (27.6%) 
Other site (n (%)) 6 (46.2%) 10 (34.5%) 
Abbreviations: 5y, treated during five years; AI, aromatase 







Title: Assessment of early therapy discontinuation and 
health‑related quality of life in breast cancer patients treated with 
aromatase inhibitors: B‑ABLE cohort study 
Summary: 
Arthralgia and enhanced bone loss are the most frequent 
adverse events of aromatase inhibitors (AI). These diminish 
patients’ quality of life and treatment adherence. This study 
assesses the early cessation of AI caused by AI intolerance, and 
the progression of joint pain and health-related quality of life 
(HRQoL) during AI treatment until 1-year after AI completion. 
Data of 910 women diagnosed with early breast cancer and 
candidates for AI were recruited in B-ABLE cohort. A survival 
analysis was conducted to study AI discontinuation, including 
Kaplan-Meier estimation and Cox regression. Patients were 
allocated in three different groups of study according to previous 
tamoxifen (TAM) exposure and length of AI treatment:  
TAM-2yAI, TAM-3yAI, and 5yAI. Visual Analog Scale (VAS)  
and ECOS-16 tests were used to evaluate joint pain and  
HRQoL in osteoporosis evolution, respectively, from baseline to  
1-year after AI completion by repeated-measures ANOVA. 
Patients previously exposed to tamoxifen had greater risk of AI 
withdrawal compared to non-exposed (adjusted HR 5.30 [95% CI 
2.23 to 12.57]). VAS and ECOS-16 scores of TAM-2yAI and 
TAM-3yAI groups increased during AI treatment, mainly during 
the first 3-12 months. After 1-year from AI completion, values 




ECOS-16 levels raised at three months, and VAS continued 
significantly higher at 1-year post-treatment. 
To conclude, AI therapy incremented joint pain and diminished 
HRQoL, especially during the first year of treatment. Patients 
switching to AI after being treated with tamoxifen experienced 
greater pain and had an excess risk of discontinuation during the 
first 12 months of AI treatment. 
Reference: 
Pineda-Moncusí M, Servitja S, Tusquets I, Diez-Perez A, Rial A, 
Cos ML, Campodarve I, Rodriguez-Morera J, Garcia-Giralt N, 
Nogués X. Assessment of early therapy discontinuation and 
health-related quality of life in breast cancer patients treated with 
aromatase inhibitors: B-ABLE cohort study. Breast Cancer Res 
Treat. 2019 Aug;177(1):53-60. Epub 2019 May 24.  































Title: Increased fracture risk in women treated with aromatase 
inhibitors versus tamoxifen: beneficial effect of bisphosphonates 
Summary: 
Aromatase inhibitors (AI) are associated with enhanced bone 
loss and an increased risk of osteoporotic fractures. To lessen 
fracture risk in these patients, oral bisphosphonates (BP) are 
currently recommended. This study aimed to evaluate the risk of 
fracture in breast cancer patients receiving AI, compared to 
tamoxifen users, and to evaluate the efficacy of BP in reducing 
fracture risk. Thus, we conducted an observational cohort study 
using data obtained from primary care records in a population 
database. Women diagnosed with breast cancer between 2006 
and 2015 and treated with tamoxifen or AI (n = 36,472) were 
stratified according to low (without osteoporosis diagnosis nor 
BP exposure) or high (with osteoporosis and/or treated with BP) 
fracture risk. Cox models were used to estimate fracture hazard 
ratios (HR [95% CI]) from the propensity score-matched patients. 
Sensitivity analyses account for competing risk of death were 
performed (subdistribution hazard ratio [SHR] [95% CI]). In 
postmenopausal women, fracture risk of AI users displayed a HR 
1.40 [95% CI: 1.05 to 1.87] and SHR 1.48 [95% CI: 1.11 to 1.98], 
compared to tamoxifen. Analyzing AI users at high risk of 
fracture, BP-treated patients had an HR 0.73 [95% CI: 0.51 to 





In summary, postmenopausal women during AI therapy had 
>40% excess risk of fracture compared to tamoxifen in real-life 
conditions, corroborating previous randomized controlled trials 
results. In high-risk patients, BP users had a significant lower 
fracture incidence during AI treatment than non-BP users. 
Monitoring fracture risk and related risk factors in AI patients is 
advisable. 
Reference: 
Pineda-Moncusí M, Garcia-Giralt N, Diez-Perez A, Servitja S, 
Tusquets I, Prieto-Alhambra D, Nogués X. Increased Fracture 
Risk in Women Treated With Aromatase Inhibitors Versus 
Tamoxifen: Beneficial Effect of Bisphosphonates. J Bone Miner 
Res. 2020 Feb;35(2):291-297. Epub 2019 Oct 31.  



























Supplemental Table 1. Baseline characteristics of >55-year-






Mean age (years) ± (SD) 69.60 ± 10.20 69.80 ± 9.48 
Mean BMI (kg/m2) ± (SD) 25.20 ± 4.56 25.20 ± 4.57 
Charlson co-morbidity index (n(%)): 
  0 223.9 (12.90%)  1,030.7 (13.10%)  
  1 72 (4.14%)  335.6 (4.25%)  
  2 964.3 (55.50%)  4,207.5 (53.30%)  
  3 316.9 (18.20%)  1,538.2 (19.50%)  
  4 or >4 160.6 (9.24%)  783.9 (9.93%)  
Smoke (n(%)):   
  Never Smokers 1,496.7 (86.10%)  6,777.3 (85.80%)  
  Current Smokers 116.2 (6.69%)  546.9 (6.93%)  
  Ex-smokers 124.8 (7.18%)  571.7 (7.24%)  
Alcoholism, n (%):   
  None/Low 1,514.2 (87.10%) 6,867.3 (87.00%) 
  Moderate 214.6 (12.30%) 989.8 (12.50%) 
  High/Alcoholic  8.9 (0.51%) 38.8 (0.49%) 
Previous fracture (n(%)) 51 (2.93%)  238.7 (3.02%)  
Previous use of systemic 
glucocorticoids (n(%)) 
19 (1.09%)  89.2 (1.13%)  
Rheumatoid arthritis (n(%)) 13.8 (0.79%)  47.1 (0.60%)  
Chronic kidney disease 
(n(%)) 
51 (2.93%)  246.7 (3.12%)  
Hypnotics/sedative (n(%)) 953.8 (54.90%)  4,450.1 (56.40%)  
All values are the mean of the ten imputed datasets.  
Abbreviations: AI-lowRF, aromatase inhibitors patients at low risk 
of fracture; BMI, body mass index; TAM-lowRF, tamoxifen patients 






Supplemental Table 2. Baseline characteristics of >55-year-







Mean age (years) ± (SD) 70.6 ± 9.36 70.6 ± 8.78 
Mean BMI (kg/m2) ± (SD) 27.6 ± 6.52 27.4 ± 6.63 
Charlson co-morbidity index (n(%)): 
  0 61.4 (12.8%) 279.7 (13.1%) 
  1 23.5 (4.92%) 98.8 (4.63%) 
  2 264.9 (55.4%) 1,173.7 (55.1%) 
  3 89.2 (18.7%) 401.6 (18.8%) 
  4 or >4 39.1 (8.18%) 178.1 (8.35%) 
Smoke (n(%)):  
  Never Smokers 419.4 (87.7%) 1,864.5 (87.5%) 
  Current Smokers 33.4 (6.99%) 156.2 (7.33%) 
  Ex-smokers 25.3 (5.29%) 111.2 (5.22%) 
Alcoholism, n (%):   
  None/Low 338.7 (70.8%) 1,523.5 (71.5%) 
  Moderate 139 (29.1%) 603.7 (28.3%) 
  High/Alcoholic  0.4 (0.08%) 4.7 (0.22%) 
Bisphosphonates use (n(%)) 306.7 (64.1%) 1,697.1 (79.6%) 
Previous fracture (n(%)) 39.1 (8.18%) 157.8 (7.40%) 
Previous use of systemic 
glucocorticoids (n(%)) 
8.5 (1.78%) 29.5 (1.38%) 
Rheumatoid arthritis (n(%)) 5.5 (1.15%) 21.5 (1.01%) 
Chronic kidney disease 
(n(%)) 
7.6 (1.59%) 40.9 (1.92%) 
Osteoporosis (n(%)) 307.3 (64.3%) 1,026.4 (48.1%) 
Hypnotics/sedative (n(%)) 282.8 (59.2%) 1,285.1 (60.3%) 
All values are the mean of the ten imputed datasets.  
Abbreviations: AI-highRF, aromatase inhibitors patients at high 
risk of fracture; BMI, body mass index; TAM- highRF, tamoxifen 






Supplemental table 3. Incidence rate from AI-highRF group 
according to different oral BPs use  




Without BP 53/795 (6.67%) 26.64 [19.47 to 33.82] 
Alendronic acid 80/2,150 (3.72%) 20.31 [15.86 to 24.76] 
Ibandronic acid 8/251 (3.19%) 16.71 [5.13 to 28.28] 
Risedronic acid 19/713 (2.66%) 13.13 [7.22 to 19.03] 
Alendronic acid plus 
cholecalciferol 
3/234 (1.28%) 7.35 [-0.97 to 15.68] 
Abbreviations: BP, bisphosphonates; CI, confidence interval; 
FX, fracture; py, person-years. 
 
Supplemental table 4. Risk of fracture in AI-highRF patients 
using different oral BPs compared to AI-highRF without BPs  
BP used HR [95%CI] SHR [95%CI] 
Alendronic acid 0.84 [0.58 to 1.23] 0.80 [0.55 to 1.16] 
Ibandronic acid 0.64 [0.27 to 1.52] 0.60 [0.25 to 1.43] 
Risedronic acid 0.47 [0.25 to 0.86] 0.43 [0.23 to 0.80] 
Alendronic acid plus 
cholecalciferol 
0.35 [0.10 to 1.21] 0.32 [0.09 to 1.09] 
Abbreviations: BP, bisphosphonates; CI, confidence interval; 






Supplemental figure 1 Cumulative hazard plot of fracture 
events within AI-highRF patients according to risk its BP 
use. Graphs show Kaplan-Meier curves representing the 
outcome of the study in terms of cumulative hazards. 






Title: Thromboembolic, cardiovascular and overall mortality risks 
of aromatase inhibitors, compared to tamoxifen treatment 
Summary: 
Among different side effects related to tamoxifen (TAM) and 
aromatase inhibitor (AI) therapies, increased risk of 
thromboembolic and cardiovascular events, respectively, 
emerged as competing causes of death. We performed an 
observational cohort study including women diagnosed with 
breast cancer and treated with TAM or AI to analyze the risk of 
thromboembolic and cardiovascular events, and the overall 
survival benefit in AI-treated patients, compared to TAM patients. 
Data were obtained from primary care records in a large 
population database (SIDIAP). Incidence rates of study 
outcomes are reported. Survival analyses included Kaplan–
Meier estimation and Cox proportional hazards models. 
Propensity score adjustment was used to minimize confounding. 
A sensitivity analysis was conducted through Fine and Gray 
models to account for competing risk of death. Data were 
available for 9,537 women treated with TAM where of these, 
3,082 were postmenopausal; and 18,455 treated with AI. 
Adjusted hazard ratios [95% confidence interval (CI)] for AI 
users, compared with postmenopausal-TAM group, were 0.93 
[95%CI: 0.69 to 1.26] for thromboembolic events; 1.13 [95%CI: 
0.79 to 1.63] for cardiovascular events, and 0.76 [95%CI: 0.70 to 




risk of pulmonary embolism (2.15 [95%CI: 0.99 to 4.64]) in AI-
treated patients. 
In conclusion, AI users had >20% lower all-cause mortality 
compared to TAM users, without increasing cardiovascular and 
thromboembolic risk. This would locate AI therapy at the first line 
in clinical practice. 
Reference: 
Pineda-Moncusí M, Garcia-Giralt N, Diez-Perez A, Tusquets I, 
Servitja S, Albanell J, Prieto-Alhambra D, Nogués X. 
Thromboembolic, cardiovascular and overall mortality risks of 
aromatase inhibitors, compared with tamoxifen treatment: an 
outpatient-register-based retrospective cohort study.  
Ther Adv Med Oncol. 2020 Mar 25;12:1758835920909660. 





































Supplementary table 1. ICD-10 codes used to identify the 














G08, I67.6, I80, I80.0, 
I80.1, I80.2, I80.3, I80.8, 
I80.9, I81, I82, I82.0, I82.1, 
I82.2, I82.3, I82.8, I82.9, 
O22.2, O22.3, O22.5, 






I20, I20.0, I20.1, I20.8, 
I20.9, I21, I21.0, I21.1, 
I21.2, I21.3, I21.4, I21.9, 
I22, I22.0, I22.1, I22.8, 
I22.9, I23, I23.0, I23.1, 
I23.2, I23.3, I23.4, I23.5, 
I23.6, I23.8, I24, I24.0, 
I24.1, I24.8, I24.9, I25, 
I25.0, I25.1, I25.2, I25.3, 




I67.0, I67.1, I67.2, I67.3, 
I67.4, I67.5, I67.6, I67.7, 
G46, G46.0, G46.1, G46.2, 
G46.3, G46.4, G46.5, 






Supplementary Table 2. Baseline characteristics of 











Mean BMI (kg/m2) ± (SD) 29.7 (5.36) 28.3 (5.53) 
 Missing, n (%) 13,555 (73.45) 7,768 (81.45) 
QMEDEA deprivation index, n (%): 
  Rural population 3,462 (20.3) 1,699 (18.9) 
  Urban area #1 3,498 (20.5) 1,748 (19.5) 
  Urban area #2 2,960 (17.4) 1,559 (17.4) 
  Urban area #3 2,692 (15.8) 1,451 (16.2) 
  Urban area #4 2,399 (14.1) 1,334 (14.9) 
  Urban area #5 2,012 (11.8) 1,181 (13.2) 
  Missing, n (% of total) 1,432 (7.76) 565 (5.92) 
Charlson co-morbidity index, n (%): 
  0 2,315 (12.5) 1,062 (11.1) 
  1 704 (3.81) 171 (1.79) 
  2 9,840 (53.3) 6,797 (71.3) 
  3 3,553 (19.3) 1,073 (11.3) 
  >=4  2,043 (11.1) 434 (4.55) 
Smoking status, n (%):   
  Never smokers 10,269 (81.4) 3,572 (60.7) 
  Current smokers 1,343 (10.7) 1,527 (25.9) 
  Ex-smokers (quit >1 year) 997 (7.9) 788 (13.4) 
  Missing, n (% of total) 5,846 (31.68) 3,650 (38.27) 
Alcoholism, n (%):   
  None/Low 2,410 (85.6) 825 (78.3) 
  Moderate 390 (13.8) 222 (21.1) 
  High/Alcoholic  16 (0.06) 6 (0.6) 
  Missing, n (% of total) 15,639 (84.74) 8,484 (88.96) 
Antiplatelet drug users 1,720 (9.32) 348 (3.65) 




Statin drug users 3,518 (19.1) 672 (7.05) 
Previous TEE history 496 (2.69) 84 (0.88) 
Previous CVE history 693 (3.76) 133 (1.39) 
All patients’ analysis, non-accounting for postmenopausal status. 
Abbreviations: AI, aromatase inhibitors; TAM, tamoxifen; BMI, 
body mass index; Q, quartile; QMEDEA, quintile MEDEA 
deprivation index; TEE, thromboembolic event; CVE, 
cerebrovascular event. 
 
Supplementary Table 3. Thromboembolic, cardiovascular 
and mortality risk of AI treatment compared with TAM 
treatment (including all TAM users). 


















































3.00 (2.14 to 4.22) 1.96 (1.37 to 2.81) 
In all patients’ analysis, non-accounting for postmenopausal 
status, AI participants were 18,455 and TAM participants 9,537. 
Adjusted results were obtained using continuous Propensity 
Score estimates. Abbreviations: HR, hazard ratio; SHR, 
subdistribution hazard ratio; CI, confidence interval; TEEs, 
thromboembolic events; CVEs, cardiovascular events. 
 
Supplementary Table 4. Risk of PE, DVT, CAD and CVD of AI 
treatment compared with TAM treatment (including all TAM 
users).  















3.24 (1.81 to 
5.79) 







1.44 (1.16 to 
1.79) 






b. Competing risk estimates  
In all patients’ analysis, non-accounting for postmenopausal 
status, AI participants were 18,455 and TAM participants 9,537. 
Adjusted results were obtained using continuous Propensity 
Score estimates. Abbreviations: HR, hazard ratio; SHR, 
subdistribution hazard ratio; CI, confidence interval; TEEs, 
thromboembolic events; PE, pulmonary embolism; DVT, deep 
vein thrombosis, phlebitis and thrombophlebitis; CVEs, 
cardiovascular events; CAD, coronary artery disease; CVD, 








3.08 (2.19 to 
4.34) 







3.08 (2.18 to 
4.36) 

















3.17 (1.78 to 
5.68) 







1.16 (0.92 to 
1.48) 








2.96 (2.10 to 
4.18) 







4.63 (0.60 to 
35.97) 





Supplementary Table 5. Risk of thromboembolic and 
cardiovascular events of AI treatment compared with TAM 
treatment (including all TAM users) using stabilized Inverse 












0.83 (0.61 to 1.14) 





0.98 (0.44 to 2.20) 











0.87 (0. 56 to 1.38)  





0.85 (0.53 to 1.39) 











0.48 (0.44 to 0.53) 
In all patients’ analysis, non-accounting for postmenopausal 
status, AI participants were 18,455 and TAM participants 9,537. 
Abbreviations: IPW HR, Inverse probability weighting hazard 
ratio; CI, confidence interval; TEEs, thromboembolic events; PE, 
pulmonary embolism; DVT, deep vein thrombosis, phlebitis and 




artery disease; CVD, cerebrovascular diseases, including stroke 

























Woman receiving AI treatment undergo to several side effects 
that must be considered for their own well-being. Reference data 
obtained from RCT could not be completely representative and 
might not capture the real extend of AI side effects.  
In order to improve patient’s quality of life and to reduce 
treatment discontinuation, this thesis has evaluated the impact of 
the most common side effects of AI in actual clinical practice 
through two approaches: using a prospective clinical cohort, B-
ABLE; and using a primary care database, SIDIAP. Based on the 
incidence of ER+ BC and the wide use of AI, this has the 
potential to help numerous women. 
There is a general awareness of a suboptimal adherence and 
persistence to AI therapy. Lack of adherence and early 
discontinuation of endocrine therapy have been related to 
increased mortality in women diagnosed with BC 107. A 
systematic review reported discontinuation rates in clinical 
practice which ranged from 31 to 73% at the end of 5 years of 
treatment, while adherence range from 41 to 72% 108. A meta-
regression analysis including almost the same studies estimated 
31.3% of AI patients ceases the treatment before reaching 5 
years 109. Entrance of generic AI (July 2010 for anastrozole and 
April 2011 for letrozole and exemestane) improved persistence 
after 36 months from diagnosis in 8%, compared to patients with 
high copays 110. In our case, B-ABLE participants showed a good 
adherence (more that 90% of patients took >80% of the pills) 
and persistence (dropout rate of 14.5% among all included 




Arthralgia, or joint pain, is one of key factors that affect both early 
cessation and life quality. Treatment cessation by arthralgia can 
be labeled as AI intolerance since patients develop an intolerable 
toxicity that causes their treatment discontinuation. Having 
arthralgia during AI treatment is extremely common 70 and is the 
main cause of AI discontinuation 111. Additionally, most of the AI 
discontinuations take place within the first year 64. Thus, 
observational studies might underestimate arthralgia scores: 
participants intolerant to AI drop out the treatment, and hence, 
the study. Missing these participants also excludes high/extreme 
pain scores from the analysis, reducing the impact of arthralgia 
when analyzing longer periods of follow-up. Furthermore, and as 
it has been observed in this work, the risk is even higher for 
patients switching from TAM. Henry et al. proposed that 
identification of patients at high risk of early discontinuation could 
allow for interventions to improve tolerance before significant 
toxicities develop 64. However, despite joint pain increment and 
AI intolerance are well-known facts, there are no consensus 
among arthralgia management. Supervision and education 
before treatment outset has been described as crucial 92, as well 
as some lifestyle modifications can reduce AI side effects 92,93. 
Moreover, switching the AI type should be preferred than 
switching to TAM since Kadakia et al. reported that two thirds of 
AI intolerant patients elongated their treatment for at least six 
months after the first AI 95.  
On the other hand, calcium and vitamin D have been identified 
as essential factors for bone health and maintenance.  




to bone turnover: a decline of plasma calcium levels increases 
bone resorption to restore them. Therefore, adequate calcium 
intake is required to maintain this balance. To that end, vitamin D 
mediates calcium absorption by small intestines 112. Moreover, 
vitamin D promotes bone resorption for maintaining calcium 
concentration in plasma. Vitamin D deficiency leads to 
decreased calcium absorption and increased osteoclasts 
formation 113. Prior studies showed that calcium and vitamin D 
supplementation prevent fractures and bone loss in elderly 
patients 114,115. Current guidelines recommend calcium and 
vitamin D assessment, including supplementation of both if 
required 100. As a note, a meta-analysis point out that calcium 
and vitamin D supplementation was inadequate to prevent BMD 
loss in patients with antiestrogenic therapy 116, but this meta-
analysis did not have a comparison group without supplements, 
and therefore cannot state a lack of effect in reducing BMD loss. 
Apart from the potential benefits of calcium and vitamin D 
supplementation in bone health, previous studies in B-ABLE 
have associated this supplementation with a relief of joint pain 
symptoms 117. 
Furthermore, Vitamin D is also involved in the correct functioning 
of the immune, muscular and nervous systems; and it might play 
a role in controlling normal breast cell growth by blocking the 
growth of cancer cells 118. In this thesis, we have observed that 
women diagnosed with breast cancer have lower vitamin D 
levels than healthy population, in special those who recently 
underwent chemotherapy. Deficiency of vitamin D has been 




or consequence 119,120. Moreover, previous studies in B-ABLE 
cohort showed better musculoskeletal outcomes in AI users with 
levels of vitamin D equal or higher to 40 ng/ml 117,121. Positive 
effects of vitamin D supplementation on BMD levels can be 
easily related to its role on bone calcium homeostasis mentioned 
above. However, its association with arthralgia decrease is not 
so clear. Vitamin D role in immune system is to modulate innate 
and adaptive immunity 122, and suitable levels of vitamin D 
reduces oxidative stress and inflammation 123. Indeed, low levels 
of vitamin D were associated with increased inflammatory 
biomarker profiles in people ≥50 years old 124. Hence, one 
explanation to arthralgia decrease is the potential anti-
inflammatory effect of Vitamin D. On the other hand, a recent 
study showed that peripheral effects of vitamin D reduced the 
inflammatory status in mice brain 125. This could be related to the 
hypothesis of central nervous system alteration by AI use72, 
explaining an improvement of joint pain outcomes through 
vitamin D supplementation. 
For all these reasons, treatment adherence and musculoskeletal 
symptoms might be improved by calcium and vitamin D 
supplementation, and hence, physicians should take it into 
account when deal with patients. In this regard, B-ABLE cohort 
not only enhance patients’ supervision, but also supplement 
them with calcium and vitamin D. These could lead to better 
outcomes than other studies, for instance, an improved 
adherence compared to RCTs (90% in B-ABLE compared to in 





Within this framework, participants from 5y-AI group (patients 
treated with AI for 5 years) without BP had a BMD reduction of 
−2.62% at LS, −3.42% at FN and −2.53% at TH, by the end of AI 
treatment. These values were much lower than values obtained 
in the ATAC trial (-6.08% at LS, -7.24% at TH), whose patients 
had no vitamin D nor calcium supplementation 76. Up to date, the 
ATAC trial is the unique RCT reporting BMD values at 5 years of 
treatment, without prior TAM exposure. Conversely, there are 
more available data on sequential treatments (TAM followed  
by AI use). When AI were introduced in the market, many  
RCT included participants previously treated with TAM, or 
incorporated a new arm by switching part of their participants.  
In B-ABLE, pTAM-AI patients without BP showed a BMD 
reduction of −3.96% at LS, −3.33% at FN and −3.01% at TH at 
the end of treatment. Slightly higher results were observed in the 
IES trial (−4.17% at LS BMD and -3.11% at TH BMD) 127, while 
MA-17 trial reported an enhanced bone loss (−5.35% at LS BMD 
and -3.60% at TH BMD) 74.  
Patients previously treated with TAM are a very interesting 
group. At the outset of AI treatment, prior TAM patients had 
similar or higher BMD values than women with AI monotherapy. 
However, they experimented a greater BMD loss during AI 
therapy, especially during the first months of treatment 128. 
Moreover, our results suggest that BMD recovery in pTAM-AI 
group after AI cessation is slower that 5y-AI group. It has been 
proposed that TAM withdrawn induces a rebound effect in  
bone 129 and, in accordance with Cohen et al. suggestion, our 




was maintained or increased in pTAM-AI patients, even though 
its increase was lower compared to 5y-AI group. In this line, 
rebound effect of TAM withdrawn could be as well associated 
with higher arthralgia and lower health‑related quality of life 
observed within the first year of follow-up of pTAM-AI group, 
explaining why previous TAM users had an excess risk of 
abandoning AI treatment within the first year. However, and in 
contrast to BMD, VAS and ECOS-16 scores of pTAM-AI group 
returned to baseline values at one-year post-treatment, while 
values were maintained in 5y-AI group. These effects could be 
attributed by age differences between pTAM groups and AI 
monotherapy since differences in baseline values (mean years 
old: 60.3 in 3yTAM-2yAI, 58.1 in 2yTAM-3yAI, and 62.8 in 5yAI; 
p<0.001) would be enlarged at the end of treatment (62.3 in 
3yTAM-2yAI, 61.1 in 2yTAM-3yAI, and 67.8 in 5yAI). 
A cohort study like B-ABLE is very valuable for obtaining highly 
detailed patient medical history, especially for laboratory data 
(i.e. bone biomarker measurements, circulating vitamin D levels, 
among others) that may not be collected in other types of 
studies. However, outcomes at low incidence require larger 
sample size. In these cases, clinical databases like SIDIAP are 
more suitable. The additional value of SIDIAP database is the 
capacity to analyze the risk of mortality, incident fractures, and 
thromboembolic and cardiovascular events of AI treatment 
compared to TAM. Moreover, studied outcomes were previously 
validated in SIDIAP 130-133, enhancing the reliability and quality of 
the data source. On top of that, SIDIAP is a big database that 




population might have an independent private health care, only a 
minority group does not have contact to the public primary care, 
and this rate is event less in issues as severe as cancer 134. 
Thus, SIDIAP sample is highly representative among European 
population treated with AI or TAM, and hence, after correcting 
indication bias by different statistical approaches, the obtained 
estimates of treatment effects could be generalized to all women 
using AI. 
Confounding by indication is an important type of confounding 
that occurs in clinical research, particularly in observational 
pharmacoepidemiologic studies. It is produced when a clinical 
indication for selecting certain treatment also affects the 
outcome, and hence randomization is not possible. In other 
words, two individuals are different since they are prescribed 
different medication 135. An example in our study: AI users are 
always postmenopausal women, but this is not required in TAM 
users and, consequently TAM group has younger patients. 
Confounding can be prevented by different procedures in the 
study design (e.g. randomization, restriction, and matching) and 
reduced by different techniques in the statistical analysis (e.g. 
stratified analyses, regression modeling, and propensity scoring) 
135. Considering that, this thesis has used different approaches to 
ensure the comparability between TAM and AI patients.  
For fracture risk estimation between TAM and AI therapies, 
sample size allowed a propensity score matching. Since 
menopause status was not available, participants were restricted 




results showed a 40% increased risk of fracture in AI patients 
compared to TAM. Additionally, a stratification of participants 
according to their baseline fracture risk was performed: 
Comparing TAM and AI patients with low risk of fracture 
(participants without evidence of osteoporosis diagnosis nor BP 
exposure), we obtained similar results than the overall analysis 
(which included all patients), probably because low-risk patients 
represented the 78.68% of the participants of the total cohort. On 
the contrary, no significant differences were observed between 
AI and TAM patients at high risk of fracture (participants with 
evidence of osteoporosis diagnosis and/or BP exposure), likely 
due to the high risk of fracture is enough important per se 
independently to the administered endocrine therapy. However, 
we cannot rule out an insufficient statistical power because of a 
lack of sample size of TAM-highRF group (n=663).  
BP use in AI-highRF group reduced the fracture risk by 27%. 
However, BP treatment was not able to reduce the fracture rate 
to the levels of AI patients group with low fracture risk at baseline 
(incidence rates: 18.57 cases/1000 person-year in AI-highRF 
using BP vs 12.32 cases/1000 person-year in AI-lowRF). 
For cardiovascular, thromboembolic and mortality risk 
estimations, TAM patients were restricted to those >55-year-old. 
Moreover, confounding was reduced by propensity score 
adjustment and inverse probability weighting adjustment. In this 
instance, age restriction was especially essential to avoid 
menopause status interaction since age and menopause have 
been described as two independent factors of cardiovascular 




a non-increased risk in cardiovascular events, and a potential 
increment of thromboembolic events in AI patients compared to 
TAM. Prior literature in cardiovascular risk of AI compared to 
TAM is inconsistent. Most of RCT and meta-analysis comparing 
AI and TAM treatments reported an excess risk of cardiovascular 
disease associated with AI use 87,89,137. However, some studies 
suggest that it might be due to cardioprotective effects of 
tamoxifen 138,139, whereas it was found that cardiovascular risk 
did not increase when AI patients were compared to controls 140. 
On the other hand, sub-analyses in a higher-risk subgroup 
(patients with prior ischemic heart disease) and lower-risk 
subgroup (aged <74 years, stage I-II BC and no prior ischemic 
heart disease) did not detect differences in cardiovascular risk 
between AI or TAM users 90. Thus, differences detected in this 
study analyzing the overall cohort could be driven by differences 
in baseline cardiovascular risk of patients. In this line, 
cardiovascular risk in Spanish women is low 141, and hence 
SIDIAP population may also have a low baseline risk. Therefore, 
exclusion of menopause effect in SIDIAP patients would match 
baseline cardiovascular risk in our analysis.  
In addition to that, death and discontinuation was considered a 
competing risk (an event that modifies the odds of the event of 
interest) for our outcomes in fracture, cardiovascular and 
thromboembolic risk analyses. This bias was managed by 
applying subdistribution hazards models (SHR) from Fine and 
Gray methodology 142. It is required to mention that wrong 
application of SHR might overestimate the obtained estimates 




estimated was 40% risk and SHR estimated was 48% in AI users 
compared to TAM, whereas HR was 27% and SHR was 31% in 
AI-highRF patients compared to AI-lowRF; while no significant 
results were detected in cardiovascular and thromboembolic 
events using both HR and SHR). 
As expected, B-ABLE and SIDIAP databases analysis showed a 
decrease in BMD and an increase of fracture risk during AI 
treatment. This bone loss was reverted, and fracture risk 
attenuated by BP use. Thus, assessment of bone status at the 
outset of AI treatment should be mandatory instead of 
recommended in order to distinguish patients at high risk of 
fracture. Up to date, the gold standard technique to assess bone 
health is still BMD measurements by DXA 37, which explains 
70% of bone strength 102. Complementary information from other 
procedures as TBS or assessment of bone remodeling markers 
could diminish BMD limitations. On the other hand, 
administration of BP should not imply a complete preservation of 
patient’s bone health that excludes the need for supervision. 
Consequently, any patient at high risk of fracture will require an 
increased monitoring of their bone health during AI treatment. 
Greater efforts for establishing a suitable assessment period are 
needed. Improving bone health and arthralgia managing of AI 
patients would have a positive impact on their quality of life and 
life expectancy derived from the reduction of pain and 
osteoporotic fractures. Moreover, fracture prevention has the 
potential to lessen the state's economic burden for incident 




All in all, this thesis emphasizes the benefits of calcium and 
vitamin D supplementation during AI treatment, especially in 
patients who had recently underwent to chemotherapy. As well 
as the importance of having a good medical advice during the 
treatment, standing out an outset bone assessment and an 
enhanced supervision of patients at high-risk of fracture and/or 
prior TAM users. These interventions provide the potential to 
improve patient’s adherence, life quality and life expectancy. 
Furthermore, B-ABLE and SIDIAP were good sources for 
monitoring existing public policies. The strategy of using both 
databases allowed us to overcome limitations linked to small or 
to large cohort studies. As a result, this thesis is an example of 
translational research, where its findings have the purpose of 
























Conclusions from the evaluation of vitamin D levels of patients 
starting AI treatment in the B-ABLE cohort: 
• Patients with ER+ BC cancer have reduced 25(OH)D levels 
compared to healthy population. 
• Recent chemotherapy is a key factor contributing to 
25(OH)D deficiency. 
• Diminished 25(OH)D levels are partially recovered over the 
long term but remained much lower than healthy population. 
• Vitamin D supplementation might improve prognosis and 
survival. Therefore, it is advisable, especially in patients 
receiving chemotherapy. 
Conclusions from the assessment of bone health in ER+ BC 
patients one year after complete AI treatment in the B-ABLE 
cohort: 
• AI-related bone loss stops at one year after AI completion in 
non-BP treated women. FN and TH BMD remains reduced, 
but LS BMD is totally recovered in most patients who 
received AI monotherapy and partially recovered in patients 
who were previously treated with TAM. 
• BP treatment increases or maintains BMD values at the end 
of therapy and at one-year post-treatment. 
• Monitoring bone health and supplement AI users with 
calcium and vitamin D is essential for the clinical 
management of patients.0 
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Conclusions from the assessment of life quality and treatment 
discontinuation of AI-treated patients in the B-ABLE cohort: 
• AI therapy increases joint pain and reduces HRQoL, mainly 
during the first year of treatment.  
• At 1-year post-treatment, joint pain and HRQoL return to 
baseline levels in patients previously treated with TAM, while 
levels on patients treated with AI monotherapy for 5 years 
remains greater than baseline. 
• The proportion of early cessation of AI treatment caused by 
AI intolerance in the B-ABLE cohort is 3.96%. 
• Patients previously treated with TAM experience greater pain 
when they switched to AI therapy and have an excess risk of 
discontinuation of 430% during the first 12 months.  
• Strictly monitoring AI patients, especially previous TAM 
users, might reduce the incidence of AI treatment 
discontinuation.  
Conclusions from the analysis of fracture incidence and risk 
during AI therapy and evaluation of the effectiveness of oral BP 
in reducing fracture risk, the SIDIAP study: 
• During AI treatment, patients at low risk of fracture have and 
incidence rate of 13.55 cases/1000 person-year, while 
patients at high risk (diagnosed with osteoporosis and/or 
treated with BP) have and incidence rate of 21.35 
cases/1000 person-year. 
• In women older than 55 years old from actual clinical 




>40% compared to TAM therapy. This corroborates previous 
RCT results. 
• In patients at high-risk of fracture during AI treatment, BP 
users have a fracture risk reduction of 30% compared to 
non-BP users. 
• Monitoring fracture risk and related risk factors in aromatase 
inhibitor patients is advisable. 
Conclusions from the analysis of cardiovascular risk, 
thromboembolic risk, and overall survival benefit of AI compared 
to TAM treatment, the SIDIAP study: 
• There is no increment in cardiovascular risk and 
thromboembolic risk between AI and TAM users. 
• AI users have >20% lower all-cause mortality compared with 
TAM users. 
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